Radiotherapy and chemotherapy in locally advanced non–small cell lung cancer: preclinical and early clinical data
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference44 articles.
1. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11.
2. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee;Saunders;Lancet,1997
3. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group;Sause;Chest,2000
4. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients;Le Chevalier;J Natl Cancer Inst,1991
5. Role of radiotherapy in combined modality treatment of locally advanced non-small-cell lung cancer;Kubota;J Clin Oncol,1994
Cited by 36 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Recent Clinical Advancements in the Combined Immunotherapy for Extensive-Stage Small Cell Lung Cancer;Asian Case Reports in Emergency Medicine;2024
2. Current Status and Progress in the Treatment of Malignant Pleural Effusion in Lung Cancer;Advances in Clinical Medicine;2023
3. Preclinical models of radiation-induced cardiac toxicity: Potential mechanisms and biomarkers;Frontiers in Oncology;2022-10-12
4. LIFE EXPECTANCY IN PATIENTS WITH STAGE III A NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH NEOADJUVANT CHEMORADIOTHERAPY (NCRT), NEOADJUVANT CHEMOTHERAPY (NCT), NEOADJUVANT CHEMOTHERAPY + ADJUVANT RADIATION THERAPY (NCT + ADJUVANT RT);Health Problems of Civilization;2022
5. PROSPECTS OF NEOADJUVANT CHEMORADIOTHERAPY IN PATIENTS WITH STAGE III A NON-SMALL CELL LUNG CANCER AS A METHOD OF IMPROVING SURVIVAL;Wiadomości Lekarskie;2022
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3